#1 - Why You Aren't Raising Capital: Joseph Snyder & Cristiano Fontana

Hosts:

Joseph Snyder

Head of Talent and Co-Founder, Lifeblood

https://www.linkedin.com/in/josephasnyder1/

Cristiano Fontana

Head of Advisory, Lifeblood

https://www.linkedin.com/in/cristiano-fontana-medtech-businessdevelopment/

Guests:

Thomas Busby

Director, Outcome Capital

Thomas F. Busby is a Director at Outcome Capital, having joined the Firm in 2015. Drawing from transactional experience spanning the breadth of life science verticals, Mr. Busby’s primary coverage and focus spans the medical device, digital health, and life sciences services segments.

Mr. Busby has advised dozens of senior management teams and Boards on a variety of complex strategic issues, ranging from transaction process considerations to valuation and transaction structure, value proposition communication and buyer analysis, along with the plethora of managerial challenges faced in executing complex corporate events. Devoted to the industry he serves, Mr. Busby has been published in leading industry publications, including: MedTech Strategist, Life Science Leader, and The Pharma Letter. Mr. Busby has also served as a panelist, moderator and judge for numerous industry events and is a Board Member of HealthTech Build, a Boston-based digital health innovation group. He also served as an External Advisory Board Member for the UMASS Chan Medical School Bridge Fund.

Umaima Ahmad

CEO, 52North

Umaima is CEO and co-founder of 52North, a multi-award winning med-tech company focused on improving urgent care. The company has raised over $11m in funding and its first product was awarded breakthrough status by the UK Government in 2024. Previously a business development professional, and a banking lawyer, Umaima has held a number of non-executive roles within health-tech. She is a seasoned negotiator of significant M&A and licensing transactions with values in the billions of dollars, involving pharmaceutical assets across multiple therapy areas which have had significant tangible impact on patient treatment pathways and health outcomes. Umaima is a graduate of King’s College London, the University of Strasbourg and BPP Law School and holds an MPhil in Bioscience Enterprise from the University of Cambridge.

https://www.linkedin.com/in/umaima-ahmad/

Tracy McNeal

CEO and President, Materna Medical

Tracy MacNeal is the CEO of Materna Medical. She is a chemical engineer, a Duke MBA, a healthcare entrepreneur, and a medical technology investor. A driver for health equity, Tracy also serves on the Board of Directors for AdvaMed, the national industry organization for medical devices, and leads their Women’s Health Equity Initiative. Tracy is President and CEO of Materna Medical, a novel, post-revenue OBGYN company with one product on the market and an exciting clinical stage product seeking to reduce maternal injury, shorten delivery time, reduce C-sections, and improve postpartum recovery for new moms.

https://www.linkedin.com/in/tracymacneal/

Martin Gomez

Partner, Goodwin Procter LLP

Martin Gomez is a partner in Goodwin’s Technology and Life Sciences Business Unit, specializing in intellectual property matters, and is a co-leader of the Firm’s MedTech and Artificial Intelligence practice groups. Martin focuses his practice on advising technology and life sciences companies of all sizes (including startups), and their investors, in corporate and especially intellectual property matters throughout the business life cycle, including new company formation, IP protection, fundraising, strat